China Universal Asset Management Co. Ltd. Increases Stock Position in Astera Labs, Inc. $ALAB

China Universal Asset Management Co. Ltd. grew its position in shares of Astera Labs, Inc. (NASDAQ:ALAB) by 175.7% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 10,200 shares of the company’s stock after purchasing an additional 6,500 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in Astera Labs were worth $922,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Charles Schwab Investment Management Inc. boosted its position in shares of Astera Labs by 4.4% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 138,300 shares of the company’s stock valued at $8,252,000 after purchasing an additional 5,828 shares during the period. National Bank of Canada FI lifted its stake in Astera Labs by 112.4% in the first quarter. National Bank of Canada FI now owns 1,149 shares of the company’s stock valued at $69,000 after buying an additional 608 shares during the last quarter. Nuveen LLC acquired a new stake in shares of Astera Labs in the first quarter valued at approximately $15,962,000. HighTower Advisors LLC boosted its holdings in shares of Astera Labs by 47.7% in the first quarter. HighTower Advisors LLC now owns 9,151 shares of the company’s stock valued at $546,000 after acquiring an additional 2,956 shares during the period. Finally, American Century Companies Inc. grew its position in shares of Astera Labs by 46.9% during the first quarter. American Century Companies Inc. now owns 6,783 shares of the company’s stock worth $405,000 after acquiring an additional 2,165 shares during the last quarter. Institutional investors and hedge funds own 60.47% of the company’s stock.

Analyst Ratings Changes

ALAB has been the subject of several research reports. Roth Capital upped their price target on shares of Astera Labs from $200.00 to $225.00 and gave the company a “buy” rating in a research report on Wednesday, November 5th. Zacks Research lowered shares of Astera Labs from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 6th. Stifel Nicolaus increased their target price on shares of Astera Labs from $185.00 to $200.00 and gave the stock a “buy” rating in a research note on Wednesday, November 5th. JPMorgan Chase & Co. raised their price target on Astera Labs from $180.00 to $215.00 and gave the stock an “overweight” rating in a report on Wednesday, November 5th. Finally, BNP Paribas began coverage on Astera Labs in a research note on Thursday, November 20th. They set an “outperform” rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat, Astera Labs currently has a consensus rating of “Moderate Buy” and an average target price of $188.17.

Insiders Place Their Bets

In related news, CEO Jitendra Mohan sold 90,459 shares of Astera Labs stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $144.69, for a total value of $13,088,512.71. Following the sale, the chief executive officer directly owned 2,080,418 shares in the company, valued at $301,015,680.42. The trade was a 4.17% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, General Counsel Philip Mazzara sold 4,620 shares of the stock in a transaction on Monday, November 17th. The stock was sold at an average price of $144.69, for a total value of $668,467.80. Following the completion of the transaction, the general counsel owned 147,040 shares of the company’s stock, valued at $21,275,217.60. The trade was a 3.05% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 586,936 shares of company stock worth $89,331,140. Corporate insiders own 12.50% of the company’s stock.

Astera Labs Stock Down 14.3%

Shares of Astera Labs stock opened at $148.85 on Monday. Astera Labs, Inc. has a 52-week low of $47.13 and a 52-week high of $262.90. The company’s 50-day simple moving average is $166.62 and its 200-day simple moving average is $154.01. The firm has a market cap of $25.14 billion, a price-to-earnings ratio of 134.10, a price-to-earnings-growth ratio of 2.77 and a beta of 1.52.

Astera Labs (NASDAQ:ALAB) last announced its quarterly earnings data on Tuesday, November 4th. The company reported $0.49 EPS for the quarter, beating analysts’ consensus estimates of $0.39 by $0.10. Astera Labs had a net margin of 27.50% and a return on equity of 13.48%. The firm had revenue of $230.58 million during the quarter, compared to the consensus estimate of $206.42 million. During the same quarter last year, the firm earned $0.23 earnings per share. The firm’s revenue was up 103.9% compared to the same quarter last year. Astera Labs has set its Q4 2025 guidance at 0.50-0.510 EPS. Equities research analysts anticipate that Astera Labs, Inc. will post 0.34 EPS for the current year.

Astera Labs Profile

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.